In the case of treatment of HER2-positive breast tumors (one of the most aggressive forms breast cancer ) Recorded significant progress. The new therapy is a combination of a conventional drug Herceptin with an experimental drug containing antibodies demonstrated the ability to curb the disease last longer than standard treatment.
Since a group of 137 patients with breast cancer new drug help retard the growth of tumors, on average, 14 months, and traditional means treatment of breast cancer in the control group was allowed to keep the tumor under control of only 9 months. Furthermore, when a new method of treatment was observed fewer side effects than conventional chemotherapy.
In the near future will require new clinical trials in patient with breast cancer Before the drug can be approved for widespread use. "This is an unusual drug - said Professor Paul Ellis of London's Guy's Hospital. - We have 20 years looking for something like this, and then, finally, got it. The medicine increases the life expectancy of the most severely ill patients, causing fewer side effects. This is the holy grail of cancer ".
The preparation consists of a protein which retrieves tumors and toxin, produced within cancer cells. This significantly reduces the damage to healthy tissue. Test drugs are in hospitals around the world, including three British hospitals. In the future, experts will conduct a study involving more patients in 1000 more than 20 countries, the results of which will be known in two years.
Industry News
Go back to the main page
Немає коментарів:
Дописати коментар